Skip to main content

Table 4 Risk of bias analysis

From: Safety and efficacy of elagolix (with and without add-back therapy) for the treatment of heavy menstrual bleeding associated with uterine leiomyomas: a systematic review and meta-analysis

Cochrane Risk of Bias Review for RCTs

Study

Random sequence generation

Allocation concealment

Blinding of personnel

Blinding of outcome assessment

Incomplete outcome data

Selective reporting

Other bias (ITT analysis)

Carr et al.

Low risk

Low risk

Low risk

Low risk

Low risk

Low risk

Low risk

Elaris (UF-1/2)

Low risk

Low risk

Low risk

Low risk

Low risk

Low risk

Low risk

Archer et al.

Unclear risk of bias

Unclear risk of bias

Unclear risk of bias

Unclear risk of bias

Low risk

Low risk

Low risk